STAT+: Merck suffers a setback in Europe over its new Keytruda formulation

RegulatoryrejectedKeytrudaNegative

AI Analysis

Summary

A Dutch court ordered Merck to halt manufacturing and marketing of a subcutaneous formulation of Keytruda in several European countries, representing a regulatory setback for the company.

Outcome Details

Dutch court ordered halt to manufacturing and marketing of subcutaneous formulation in several European countries

Importance:7/10

Sentiment:

-0.80

regulatoryEuropelegalformulationKeytruda

Related Companies

$MRK

Read the original article

Published by STAT News on October 7, 2026 2:06 PM

Read Original